Ibuprofen lysine for the prevention and treatment of patent ductus arteriosus

Pharmacotherapy

Volumn 28, Issue 9, 2008, Pages 1162-1182

  Pai, Vinita B ^a   Sakadjian, Arpi ^b   Puthoff, Teresa D ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Ibuprofen lysine; Indomethacin; Patent ductus arteriosus; PDA; Prevention; Treatment

Indexed keywords

IBUPROFEN LYSINE; INDOMETACIN;

BIRTH WEIGHT; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CORONARY HEMODYNAMICS; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECHOCARDIOGRAPHY; FETUS CIRCULATION; FOLLOW UP; GESTATIONAL AGE; HUMAN; KIDNEY BLOOD FLOW; LOADING DRUG DOSE; MESENTERY BLOOD FLOW; NECROTIZING ENTEROCOLITIS; OLIGURIA; PATENT DUCTUS ARTERIOSUS; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; URINE VOLUME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DUCTUS ARTERIOSUS, PATENT; FEMALE; FETUS; HUMANS; IBUPROFEN; INDOMETHACIN; INFANT, NEWBORN; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGIONAL BLOOD FLOW;

EID: 51849137380     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.9.1162     Document Type: Review

References (99)

1. Hammerman C. Patent ductus arteriosus: clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol 1995;22:457-79.
2. Noel S, Cassin S. Maturation of contractile response of ductus arteriosus to oxygen and drugs. Am J Physiol 1976;231:240-3.
3. Hermes-DeSantis ER, Clyman RI. Patent ductus arteriosus: pathophysiology and management. J Perinatol 2006;26:S14-18.
4. Hansen T, Corbet A. Chronic lung disease: bronchopulmonary dysplasia. In: Taeusch HW, Ballard RA, eds. Avery's diseases of the newborn. Philadelphia: WB Saunders, 1998:634.
5. Yoder BA, Siler-Khodr T, Winter VT, Coalson JJ. High-frequency oscillatory ventilation: effects on lung function, mechanics, and airway cytokines in the immature baboon model for neonatal chronic lung disease. Am J Respir Crit Care Med 2000;162:1867-76.
6. Delemos RA, Coalson JJ, Gerstmann DR, Kuehl TJ, Null DM Jr. Oxygen toxicity in the premature baboon with hyaline membrane disease. Am Rev Respir Dis 1987;136:677-82.
7. Meredith KS, deLemos RA, Coalson JJ, et al. Role of lung injury in the pathogenesis of hyaline membrane disease in premature baboons. J Appl Physiol 1989;66:2150-8.
8. Takata M, Abe J, Tanaka H, et al. Intraalveolar expression of tumor necrosis factor-alpha gene during conventional and high-frequency ventilation. Am J Respir Crit Care Med 1997;156:272-9.
9. Martin GR, Short BL. Doppler echocardiographic evaluation of cardiac performance in infants on prolonged extracorporeal membrane oxygenation. Am J Cardiol 1988;62:929-34.
10. Clyman RI, Mauray F, Heymann MA, Roman C. Influence of increased pulmonary vascular pressures on the closure of the ductus arteriosus in newborn lambs. Pediatr Res 1989;25:136-42.
11. Clyman RI, Waleh N, Black SM, et al. Regulation of ductus arteriosus patency by nitric oxide in fetal lambs: the role of gestation, oxygen tension and vasavasorum. Pediatr Res 1998;43:633-44.
12. Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med 2000;343:728-9.
13. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976;295:530-3.
14. Mahony L, Carnero V, Brett C, Heymann MA, Clyman RI. Prophylactic indomethacin therapy for infants. N Engl J Med 1982;306:506-10.
15. Yeh TF, Luken JA, Thalji A, Raval D, Carr I, Pildes RS. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus: a double blind controlled study. J Pediatr 1981;98:137-45.
16. Merritt TA, Harris JP, Roghmann K, et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. J Pediatr 1981;99:281-6.
17. Gersony WM, Peckham GJ, Ellison CR, Miettinen OS, Nadas AS. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983;102:895-906.
18. Cotton RB, Haywood JL, Fitzgerald GA. Symptomatic patent ductus arteriosus following prophylactic indomethacin: a clinical and biochemical appraisal. Biol Neonate 1991;60:273-82.
19. Rennte JM, Doyle J, Cooke RWI. Early administration of indomethacin to preterm infants. Arch Dis Child 1986;61:233-8.
20. Krueger E, Mellander M, Bratton D, Cotton R. Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin. J Pediatr 1987;111:749-54.
21. Bada HS, Green RS, Pourcyrous ML, et al. Indomethacin reduces the risks of severe intraventricular hemorrhage. J Pediatr 1989;115:631-7.
22. Ment LR, Oh W, Ehrenkranz RA, et al. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics 1994;93:543-50.
23. Laudignon N, Chemtob S, Bard H, Aranda JV. Effects of indomethacin on cerebral blood flow velocity of premature newborns. Biol Neonate 1988;54:254-62.
24. Van Bel F, Van de Bor M, Stijnen T, Baan J, Ruys JH. Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: duration of its effects. Pediatrics 1989;84:802-7.
25. Lundell BPW, Sonesson SE, Sundell H. Cerebral blood flow following indomethacin administration. Dev Pharmacol Ther 1989;13:139-44.
26. Austin NC, Pairaudeau PW, Hames TK, Hall MA. Regional blood flow velocity changes after indomethacin infusion in preterm infants. Arch Dis Child 1992;67:851-4.
27. Pryds O, Greisen G, Johansen KH. Indomethacin and cerebral blood flow in premature infants treated for patent ductus arteriosus. Eur J Pediatr 1988;147:315-16.
28. Edwards AD, Wyatt JS, Richardson C, et al. Effects of indomethacin on cerebral hemodynamics in very preterm infants. Lancet 1990;335:1491-5.
29. Liem KD, Hopman JCW, Kolle LAA, Oeseburg B. Effects of repeated indomethacin administration on cerebral oxygenation and hemodynamics in preterm infants: combined NlRS and Doppler ultrasound study. Eur J Pediatr 1994;153:504-9.
30. Hammerman C, Glaser J, Schimmel MS, et al. Continuous versus multiple rapid infusions of indomethacin: effects on cerebral blood flow velocity. Pediatrics 1995;95:244-8.
31. Betkerur MV, Yeh TF, Miller K, Glasser RJ, Pildes RS. Indomethacin and its effects on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics 1981;68:99-102.
32. Van Bel F, Guit GL, Schipper J, van de Bor M, Baan J. Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr 1991;118:621-6.
33. Chemtob S, Beharry K, Barna T, Varma DR, Aranda JV. Differences in the effects in the newborn piglet of various non-steroidal anti-inflammatory drugs on cerebral blood flow but not on cerebrovascular prostaglandins. Pediatr Res 1991;30:106-11.
34. Pellicer A, Aparicio M, Cabañas F, Valverde E, Quero J, Stiris TA. Effect of the cyclo-oxygenase blocker ibuprofen on cerebral blood volume and cerebral blood flow during normocarbia and hypercarbia in newborn piglets. Acta Pediatr 1999;88:82-8.
35. U.S. Food and Drug Administration. List of orphan designated approved products. Available from www.fda.gov/orphan/designat/approvytd.rtf. Accessed August 6, 2006.
36. Ovation Pharmaceuticals. NeoProfen (ibuprofen lysine) package insert. Deerfield, IL, 2006.
37. Young TE, Magnum B. Neofax: a manual of drugs used in neonatal care. Montvale, NJ: Thomson Healthcare, 2007:138.
38. Mosca F, Bray M, Lattanzio M, Fumagalli M, Tosetto C. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 1997;131:549-54.
39. Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards AD. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 2000;47:36-41.
40. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli F. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999;135:733-8.
41. Van Overmeire B, Follens I, Hartmann S, Creten WL, Van Acker KJ. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonatal Ed 1997;76:F179-84.
42. Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000;343:674-81.
43. Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr 2002;161:202-7.
44. Su PH, Chen JY, Su CM, Huang TC, Lee HS. Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Pediatr Int 2003;45:665-70.
45. Fanos V, Benini D, Verlato G, Errico G, Cuzzolin L. Efficacy and renal tolerability of ibuprofen vs. indomethacin in preterm infants with patent ductus arteriosus. Fundam Clin Phamacol 2005;19:187-93.
46. Aly H, Lotfy W, Badrawi N, Ghawas M, Abdel-Meguid IE, Hammad TA. Oral Ibuprofen and ductus arteriosus in premature infants: a randomized pilot study. Am J Perinatol 2007;24:267-70.
47. Cherif A, Jabnoun S, Khrouf N. Oral ibuprofen in early curative closure of patent ductus arteriosus in very premature infants. Am J Perinatol 2007;24:339-45.
48. Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study [online exclusive article]. Pediatrics 2003;112:e354. Available from http://pediatrics.aappublications.org/cgi/content/full/112/5/ e354.
49. Sharma PK, Garg SK, Narang A. Pharmacokinetics of oral ibuprofen in premature infants. J Clin Pharmacol 2003;43:968-73.
50. Tatli MM, Kumral A, Duman N, Demir K, Gurcu O, Ozkan H. Spontaneous intestinal perforation after oral ibuprofen treatment of patent ductus arteriosus in two very-low-birth weight infants. Acta Paediatr 2004;93:999-1001.
51. Perlman MM, Rollins N, Burns D, Risser R. Relationship between periventricular intraparenchymal echodensities and germinal matrix- intraventricular hemorrhage in the very low birth weight neonate. Pediatrics 1993;91:474-80.
52. Shankaran S, Bauer CR, Bain R, Wright LL, Zachary J. Prenatal and perinatal risk and protective factors for neonatal intracranial hemorrhage. Arch Pediatr Adolesc Med 1996;150:491-7.
53. Volpe JJ. Intraventricular hemorrhage in the premature infant: current concepts - part II. Ann Neurol 1989;25:109-16.
54. Whitaker AG, Feldman JF, Rosen RV, et al. Neonatal cranial ultrasound abnormalities in low birth weight infants: relation to cognitive outcomes at six years old. Pediatrics 1996;98:719-29.
55. McMenamin JB, Shackelford GD, Volpe JJ. Outcome of neonatal intraventricular hemorrhage with periventricular echodense lesions. Ann Neurol 1984;15:285-90.
56. Szymonowicz W, Yu VYH, Bajuk B, Astbury J. Neurodevelopmental outcome of periventricular hemorrhage and leukomalacia in infants. Early Hum Dev 1986;14:1-7.
57. Vohr B, Ment LR. Intraventricular hemorrhage in the preterminfant. Early Hum Dev 1996;44:1-16.
58. Vohr B, Garcia-Coll C, Flanagan P, Oh W. Effects of intraventricular hemorrhage and socioeconomic status on the perceptual, cognitive, and neurologic status of low birth weight infants at 5 years of age. J Pediatr 1992;121:280-5.
59. Horbar JD. Prevention of periventricular-intraventricular hemorrhage. In: Sinclair J, Bracken MB, eds. Effective care of the newborn infant. Oxford, England: Oxford University Press, 1992:562-89.
60. Bandstra ES, Montalvo BM, Goldberg RN, et al. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. Pediatrics 1988;82:533-42.
61. Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2002;(3):CD000174.
62. Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth weight infants. N Engl J Med 2001;344:1966-72.
63. Ment LR, Vohr B, Allan W, et al. Outcome of children in the inodmethacin intraventricular hemorrhage prevention trial. Pediatrics 2000;105:485-91.
64. Varvarigou A, Bardin CL, Beharry K, Chemtob S, Papageorgiou A, Aranda JV. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA 1996;275:539-44.
65. Dani C, Bertini G, Reali MF, et al. Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants. Acta Paediatr 2000;89:1369-74.
66. De Carolis MP, Romagnoli C, Polineni V, et al. Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants. Eur J Pediatr 2000;159:364-8.
67. Gournay V, Rozé JC, Kuster A, et al. Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1939-44.
68. Van Overmeire B, Allegaert K, Casaer A. Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1945-9.
69. Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2008;(1):CD003481.
70. 2 delivery to the fetal ductus arteriosus: implications for postnatal patency. Am J Physiol Regul Integr Comp Physiol 2002;282:R184-90.
71. Clyman RI, Chen YQ, Chemtob S, et al. In utero remodeling of the fetal lamb ductus arteriosus: the role of antenatal indomethacin and avascular zone thickness on vasa vasorum proliferation, neointima formation, and cell death. Circulation 2001;103:1806-12.
72. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2001;(3):CD000503.
73. Collaborative Group of Antenatal Steroid Therapy. Prevention of respiratory distress syndrome: effect of antenatal steroid administration. National Institutes of Health publication no. 85-2695. Washington, DC: U.S. Government Printing Office, 1985:1-34.
74. Narayanan M, Cooper B, Weiss H, Clyman RI. Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. J Pediatr 2000;136:330-7.
75. Brash AR, Hickey DE, Graham TP, Oates JA, Cotton RB. Pharmacokinetics of indomethacin in the neonate. N Engl J Med 1981;305:67-72.
76. Thalji AA, Carr I, Yeh TF, Raval D, Luken JA, Pildes RS. Pharmacokinetics of intravenously administered indomethacin in premature infants. J Pediatr 1980;97:995-1000.
77. Gal P, Ransom JL, Shaffer CL, et al. Reopening of the ductus arteriosus after closure with indomethacin: importance of sustained effective indomethacin serum concentrations [letter]. J Pediatr 1996;128(5 pt 1):719.
78. Clyman RI, Seidner S, Koch C. Combined prostaglandin and nitric oxide inhibition produces permanent closure of the PDA in premature baboons [abstract]. Pediatr Res 1999;45:190A.
79. Achanti B, Yeh TF, Pildes RS. Indomethacin therapy in infants with advanced postnatal age and patent ductus arteriosus. Clin Invest Med 1986;9:250-3.
80. Shaffer CL, Gal P, Ransom JL, et al. Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med 2002;30:343-8.
81. Sperandio M, Beedgen B, Feneberg R, et al. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. Pediatrics 2005;116:1361-6.
82. Van Overmeire B, Touw D, Schepens PJC, Kearns G, van den Anker JN. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther 2001;70:336-43.
83. Walson PD, Mortensen ME. Pharmacokinetics of common analgesics, anti-inflammatories and anti-pyretics in children. Clin Pharmacokinet 1989;17(suppl):116-37.
84. Mills RFN, Adams SS, Cliffe EE, et al. The metabolism of ibuprofen. Xenobiotica 1973;3:589-98.
85. Aranda JV, Varvarigou A, Beharry K, Bansal R, Bardin C, Modanlau H. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infants. Acta Pedaitr 1997;86:289-98.
86. Ahlfors CE. Unbound bilirubin associated with kernicterus: a historical approach. J Pediatr 2000;137:540-4.
87. Brodersen R. Competitive binding of bilirubin and drugs to human serum albumin studied by enzymatic oxidation. J Clin Invest 1974;54:1353-64.
88. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. Anal Biochem 2000;279:130-5.
89. Silverman WA, Andersen DH, Blanc WA, Crozier DN. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 1956;18:614-24.
90. Ahlfors CE. Effect of ibuprofen on bilrrubin-albumin binding. J Pediatr 2004;144:386-8.
91. Gournay V, Savagner C, Thiriez G, Kuster A, Rozé JC. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 2002;359:1486-8.
92. Bellini C, Campone F, Serra G. Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. Can Med Assoc J 2006;174:1843-4.
93. Romagnoli C, De Carolis MP, Papacci P, et al. Effects of prophylactic ibuprofen on cerebral and renal hemodynamics on very preterm neonates. Clin Pharmacol Ther 2000;67:676-83.
94. Anonymous. Red book. Montvale, NJ: Thomson Healthcare, 2007.
95. United States Pharmacopeial Convention. Chapter 797: pharmaceutical compounding - sterile preparations. In: United States Pharmacopeia 30-National Formulary 25. Rockville, MD: The United States Pharmacopeial Convention, 2007:334-51.
96. Van Overmeire B. Common clinical and practical questions on the use of intravenous ibuprofen lysine for the treatment of patent ductus arteriosus. J Pediatr Pharmacol Ther 2007;12:194-206.
97. Walker SE, Gray S, Schmidt B. Stability of reconstituted indomethacin sodium trihydrate in original vials and polypropylene syringes. Am J Hosp Pharmacy 1998;55:154-8.
98. Anonymous. Red book. Montvale, NJ: Thomson Healthcare, 2005.
99. Anonymous. Red book. Montvale, NJ: Thomson Healthcare, 2006.